Equities research analysts expect Endologix Inc (NASDAQ:ELGX) to report $41.33 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for Endologix’s earnings. The highest sales estimate is $41.52 million and the lowest is $40.80 million. Endologix posted sales of $42.61 million in the same quarter last year, which suggests a negative year-over-year growth rate of 3%. The company is expected to report its next quarterly earnings results after the market closes on Wednesday, May 2nd.
On average, analysts expect that Endologix will report full-year sales of $174.70 million for the current year, with estimates ranging from $173.70 million to $175.88 million. For the next financial year, analysts anticipate that the company will post sales of $184.48 million per share, with estimates ranging from $179.72 million to $193.50 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Endologix.
Endologix (NASDAQ:ELGX) last issued its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.13. Endologix had a negative return on equity of 44.91% and a negative net margin of 36.65%. The firm had revenue of $44.00 million for the quarter, compared to analysts’ expectations of $44.91 million. During the same period in the previous year, the firm posted ($0.30) earnings per share. The business’s revenue was down 7.3% compared to the same quarter last year.
NASDAQ ELGX traded down $0.07 during trading hours on Friday, hitting $4.11. 1,949,904 shares of the company were exchanged, compared to its average volume of 655,642. The company has a debt-to-equity ratio of 2.77, a current ratio of 2.36 and a quick ratio of 1.62. Endologix has a 52 week low of $3.75 and a 52 week high of $7.66. The stock has a market capitalization of $354.16, a P/E ratio of -8.56 and a beta of 0.32.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. ArrowMark Colorado Holdings LLC grew its stake in shares of Endologix by 11.8% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 9,890,106 shares of the medical instruments supplier’s stock valued at $52,912,000 after buying an additional 1,043,986 shares during the last quarter. BlackRock Inc. grew its stake in shares of Endologix by 1.1% during the fourth quarter. BlackRock Inc. now owns 5,093,047 shares of the medical instruments supplier’s stock valued at $27,248,000 after buying an additional 56,745 shares during the last quarter. Senzar Asset Management LLC grew its stake in shares of Endologix by 143.6% during the fourth quarter. Senzar Asset Management LLC now owns 2,196,225 shares of the medical instruments supplier’s stock valued at $11,750,000 after buying an additional 1,294,684 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Endologix by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 721,491 shares of the medical instruments supplier’s stock valued at $3,859,000 after buying an additional 24,703 shares during the last quarter. Finally, Prosight Management LP bought a new position in shares of Endologix during the fourth quarter valued at approximately $3,509,000.
TRADEMARK VIOLATION NOTICE: “$41.33 Million in Sales Expected for Endologix Inc (ELGX) This Quarter” was originally reported by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/13/41-33-million-in-sales-expected-for-endologix-inc-elgx-this-quarter.html.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.